In addition, the expression profiles of all cabozantinib targets tested (MET, VEGFR2, AXL, RET, and KIT) in LuCaP PCa xenografts demonstrate that all of these targets are expressed in advanced PCa. This evidence concerns the gene KDR and posterior cortical atrophy.